Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy.

Abstract excerpt

Osteosarcoma (OS) is the most common primary bone malignancy and is frequently lethal via metastasis to the lung. While surgical techniques and adjuvant chemotherapies have emerged to combat this deadly cancer, the 5-year survival rate has plateaued over the past four decades. Therapeutic progress has been notably poor because past technologies have not been able to reveal obscured OS biomarkers and targets. With...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Biomarkers, Tumor
• Bone Neoplasms
• Gene Expression Regulation, Neoplastic
• High-Throughput Nucleotide Sequencing